A patient self-assessment software combining compliance protocols to improve prescriber confidence, reduce liability, and improve patient outcomes.

患者自我评估软件结合了依从性协议,可提高处方者的信心、减少责任并改善患者的治疗结果。

基本信息

  • 批准号:
    10226096
  • 负责人:
  • 金额:
    $ 93.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-01 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT ABSTRACT The current overdose epidemic is being fueled by widespread, non-medical use of opioids prescribed by mostly well-meaning physicians with inadequate training on how to properly initiate, monitor and discontinue opioid therapy. Many patients being initiated on chronic opioid therapy have factors putting them at higher risk for substance misuse and possible future overdose, however the typical primary care visit for a new patient is too short for a thorough evaluation. This puts patients at risk by perpetuating a substandard level of care, and puts prescribers at risk by lacking substantiated documentation to support the legal standard “legitimate medical purpose”. Most current measures aimed at solving the opioid epidemic have not considered the biggest obstacle to appropriate patient care and good medicolegal documentation, which is time. To complicate the matter, many physicians are simply refusing to prescribe opioids for fear of criminal, civil or regulatory intervention. This is compounding the issue by inundating clinics that do prescribe opioids with new, unverified patients that are often almost out of medication or already in withdrawal. This common scenario is contributing to the steady rise of fentanyl and other synthetic opioid related overdose deaths by pushing patients with pain, dependence and addiction to seek help through illegal means. The Care Continuity Program (CCP), a product of Sure Med Compliance, is a novel, online patient self-assessment used by prescribers of opioids to better identify patient risk factors and therapy benefit. This tool is completed by the patient, outside of the office, using an internet enabled device and follows a compliance driven protocol developed by analyzing case law against physicians in mis-prescribing opioid cases. Results, in the form of a date and time stamped legal report, are instantly transmitted to the prescriber’s electronic health records, mitigating the prescriber’s civil and criminal risk. A brief of findings is displayed within the software through a dashboard and on the summary page of the report. This software offering includes a mobile and standard web-based application. The objective of the proposed research is to validate the protocols and delivery system of the CCP by measuring patient outcomes, prescriber confidence, and completeness of documentation in the patient chart in primary care and pain management settings, pre and post implementation of the CCP.
项目摘要 当前的过量流行是通过宽度,非医学使用的卵子的流行 大多数善意的医生规定了有关如何正确正确的培训 启动,监测和停止绿木疗法。许多患者是在慢性元素类药物上启动的 治疗的因素使他们面临滥用物质的风险和可能的未来 过量服用,但是新患者的典型初级保健访问太短了,无法进行全面评估。 这使患者通过不合格的护理水平使患者处于危险之中,并通过缺乏处方者处方 证实文件以支持法律标准“合法医疗目的”。大多数当前的措施 旨在解决阿片类药物流行的尚未考虑适当的患者护理和 好的媒体文档,这是时候了。为了使事情复杂化,许多医生只是拒绝 开处方阿片类药物,因为担心犯罪,民事或法规干预。这是通过 用新的未经验证的患者开出阿片类药物的淹没诊所,这些诊所通常几乎是用药 或已退出。这种常见的情况有助于芬太尼和其他合成的稳定上升 阿片类药物相关的过量死亡通过推动疼痛,依赖和成瘾的患者寻求帮助 非法手段。护理连续性计划(CCP)是一种肯定MED合规性的产品,是一种新颖的在线患者 阿片类药物处方者使用的自我评估可以更好地识别患者的危险因素和治疗益处。这个工具 由患者在办公室外部完成,使用启用Internet设备完成,并遵循合规性 通过分析针对医师的判例法在错误处方阿片类药物案件中进行的驱动方案。结果,在 日期和时间盖章法律报告的形式立即传输到处方者的电子健康 记录,减轻处方者的民事和刑事风险。软件中显示了发现的简介 通过仪表板和报告的摘要页面。该软件产品包括手机和 标准基于Web的应用程序。拟议研究的目的是验证协议和交付 CCP系统通过衡量患者的结果,处方者的信心和文档的完整性 在初级保健和疼痛管理环境中的患者图表中,CCP的实施前后。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A Population-Based Study.
  • DOI:
    10.1007/s40264-022-01267-z
  • 发表时间:
    2023-03
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Wang, Shuang;Meador, Kimford J.;Pawasauskas, Jayne;Lewkowitz, Adam K.;Ward, Kristina E.;Brothers, Todd N.;Hartzema, Abraham;Quilliam, Brian J.;Wen, Xuerong
  • 通讯作者:
    Wen, Xuerong
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ABRAHAM G HARTZEMA其他文献

ABRAHAM G HARTZEMA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ABRAHAM G HARTZEMA', 18)}}的其他基金

A patient self-assessment software combining compliance protocols to improve prescriber confidence, reduce liability, and improve patient outcomes.
患者自我评估软件结合了依从性协议,可提高处方者的信心、减少责任并改善患者的治疗结果。
  • 批准号:
    10013399
  • 财政年份:
    2020
  • 资助金额:
    $ 93.41万
  • 项目类别:
HIT for Medication Safety in Critical Access Hospitals
HIT 促进关键医院的用药安全
  • 批准号:
    6890734
  • 财政年份:
    2004
  • 资助金额:
    $ 93.41万
  • 项目类别:

相似国自然基金

基于rAAV的基因替代疗法治疗CARD9缺陷相关的侵袭性皮肤癣菌感染研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    56 万元
  • 项目类别:
    面上项目
基于rAAV的基因替代疗法治疗CARD9缺陷相关的侵袭性皮肤癣菌感染研究
  • 批准号:
    82173428
  • 批准年份:
    2021
  • 资助金额:
    56.00 万元
  • 项目类别:
    面上项目
经玻璃体腔基因替代疗法联合抗凋亡基因疗法治疗LCA2及抗凋亡分子机制探索
  • 批准号:
    81970840
  • 批准年份:
    2019
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
铁影响雌激素替代疗法在绝经早晚期对动脉粥样硬化疗效的差异
  • 批准号:
    81870348
  • 批准年份:
    2018
  • 资助金额:
    56.0 万元
  • 项目类别:
    面上项目
冠心病患者PCI术后西洛他唑替代疗法的可行性及药理机制研究
  • 批准号:
    81803630
  • 批准年份:
    2018
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Vertical Sleeve Gastrectomy for Treatment of NASH: a pilot randomized control
垂直袖状胃切除术治疗 NASH:试点随机对照
  • 批准号:
    10185737
  • 财政年份:
    2021
  • 资助金额:
    $ 93.41万
  • 项目类别:
Vertical Sleeve Gastrectomy for Treatment of NASH: a pilot randomized control
垂直袖状胃切除术治疗 NASH:试点随机对照
  • 批准号:
    10450031
  • 财政年份:
    2021
  • 资助金额:
    $ 93.41万
  • 项目类别:
Vertical Sleeve Gastrectomy for Treatment of NASH: a pilot randomized control
垂直袖状胃切除术治疗 NASH:试点随机对照
  • 批准号:
    10631958
  • 财政年份:
    2021
  • 资助金额:
    $ 93.41万
  • 项目类别:
Novel approaches to identify and quantify the impact of drug-drug interactions in older adults with diabetes, with a focus on multimorbidity and polypharmacy
识别和量化老年糖尿病患者药物相互作用影响的新方法,重点关注多发病和多药治疗
  • 批准号:
    10599953
  • 财政年份:
    2021
  • 资助金额:
    $ 93.41万
  • 项目类别:
Novel approaches to identify and quantify the impact of drug-drug interactions in older adults with diabetes, with a focus on multimorbidity and polypharmacy
识别和量化老年糖尿病患者药物相互作用影响的新方法,重点关注多发病和多药治疗
  • 批准号:
    10214966
  • 财政年份:
    2021
  • 资助金额:
    $ 93.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了